Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiglitazar Sodium Effects on Metabolism in T2DM
NCT06191328Not yet recruiting
- Start
- Jan 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of chiglitazar in type 2 diabetes mellitus (T2DM). Primary endpoint: Hemoglobin A1c at 12 weeks. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
chiglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06191328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06191328.